Results 71 to 80 of about 2,777,051 (310)
Discussing Identities through Game-Making: A Case Study [PDF]
, 2016 Identities should not be understood as a static, defining trait, but as a temporary articulation performed by diverse people. Based on data generated through the Playing Beowulf project, in which students produced their own games, I present a reflection ...
de Paula, Bruno Henrique
core
Molecular Oncology, EarlyView.Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla +9 more
wiley +1 more source
Startup Method and Strategy for Bipolar LCC-HVDC System Used as Black-Start Power Source
Zhongguo dianliThe scientific and reasonable black-start scheme is the most effective measure to cope with the power grid blackout, which can greatly accelerate the system recovery process, thus significantly reducing the losses of power system due to power failure ...
Qingwei WANG +3 more
doaj +1 more source
Editorial: Ten Years of Press Start [PDF]
Editorial for the May 2024 ...
Gómez, Sebastián +12 more
core
Becoming Halfling: Racial Permeability as Ludonarrative Architecture in Critical Role
, 2023 Livestreamed play of tabletop games affords a new medium for analysis of racialization for game studies. For Dungeons & Dragons 5th edition (Multiple authors, 2014) actual plays, audiences can engage with racialized narratives in underappreciated ...
Hines, Mark
core
CCDC80 suppresses high‐grade serous ovarian cancer migration via negative regulation of B7‐H3
Molecular Oncology, EarlyView.PAX8 is a lineage‐specific master regulator of transcription in high‐grade serous ovarian cancer (HGSC) progression. We show for the first time that PAX8 facilitates proliferation and metastasis by repressing the cell autonomous tumor suppressor CCDC80 and inducing B7‐H3 expression.
Aya Saleh +12 more
wiley +1 more source
Editorial: March 2019 (Vol. 5, Issue 1)
, 2019 Over the past year, we’ve had a change of hands from our founder, Matt Barr, to our new editor-in-chief, Mahli-Ann Butt. We’ve taken some extra time to put together this issue with great pride and care.
Thomson, Reece +7 more
core
Finding novel vulnerabilities of hypomorphic BRCA1 alleles
Molecular Oncology, EarlyView.Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder +10 more
wiley +1 more source
Molecular Oncology, EarlyView.Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi +14 more
wiley +1 more source
Molecular Oncology, EarlyView.Interferon type 1 (IFN‐1) production and signaling is associated with the acquisition of therapy resistance, following chronic DNA damage, via Interferon‐related DNA damage resistance signature (IRDS) gene expression. An alternative, DNA damage‐independent role of sustained IFN‐1 mediated resistance was identified and characterized by the emergence of ...
Ashlyn Conant +11 more
wiley +1 more source